Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Dr Brian Kennedy explains why verifying longevity interventions work is key and why the transition to human trials is so important.

Brian Kennedy is one of the busiest people in the longevity business, with fingers in many of the most interesting antiaging pies. He was at the Longevity Investors Conference recently, discussing some of the latest discoveries in longevity research and giving a longevity industry overview.

The Longevity Investors Conference (LIC) is the world’s leading and most private longevity-focused investors-only conference. Providing relevant insights into the fast-growing field of longevity, the conference also offers expert education and investment opportunities, as well as fostering excellent networking opportunities. It was our privilege to attend and talk to so many key opinion leaders.

Visit Longevity. Technology — https://bit.ly/3PwtH8Y

Continue reading “Dr Brian Kennedy — validating aging interventions and why rapamycin is the gold standard” | >

The lone volunteer in a unique study involving a gene-editing technique has died, and those behind the trial are now trying to figure out what killed him.

Terry Horgan, a 27-year-old who had Duchenne muscular dystrophy, died last month, according to Cure Rare Disease, a Connecticut-based nonprofit founded by his brother, Rich, to try and save him from the fatal condition.

Although little is known about how he died, his death occurred during one of the first studies to test a gene editing treatment built for one person. It’s raising questions about the overall prospect of such therapies, which have buoyed hopes among many families facing rare and devastating diseases.

Read more | >

Dr Charles Brenner on the longevity understanding disconnect, the best interventions for longevity, and the NR trials he’d like to see.

The Longevity Investors Conference is a key event for those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. The world’s leading and most private longevity-focused investors-only conference, LIC attracts some of the most prominent thought leaders.

One of those thought leaders is Charles Brenner, the biochemist whose work on nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, includes the discovery of nicotinamide riboside (NR) kinase pathway and the resulting tech that led to the development of NR as an NAD-booster.

As Eric Verdin did recently, Brenner is one for driving the longevity debate, even if it causes more than a few ripples, and in cautioning against overstating progress, he is a significant calibration point for our industry (Twitter wars, notwithstanding). We were able to grab a few moments with Brenner at LIC to find out more about his thoughts on the current state of play.

Continue reading “Dr Charles Brenner: longevity is not a simple engineering problem” | >

A major hallmark of Parkinson’s disease is the loss of dopamine-producing neurons in the brain, which in turn causes patients to lose motor control abilities. NYSCF – Robertson Stem Cell Investigator Alumna Malin Parmar, PhD, of Lund University, has spent a decade developing a cell therapy to replace these cells, and this revolutionary treatment (called ‘STEM-PD’) has just received approval for a Phase I/IIa clinical trial in Sweden.

“We are excited and looking forward to this clinical study of STEM-PD, hoping that it could potentially help reduce the significant burden of Parkinson’s disease. This has been a massive team effort for over a decade, and the regulatory approval is a major and important milestone,” said Dr. Parmar, who is a Professor of Developmental and Regenerative Neurobiology at Lund, in a statement.

Dr. Parmar’s innovative work towards a Parkinson’s cell therapy earned her the NYSCF – Robertson Stem Cell Investigator Award in 2016, which provided support for her lab’s research until 2021, including her work on STEM-PD.

Read more | >

Join us on November 9 to learn how to successfully innovate and achieve efficiency by upskilling and scaling citizen developers at the Low-Code/No-Code Summit. Register here.

Forrester Research’s recently-released predictions report for artificial intelligence highlights what most have already observed: AI adoption has evolved from an emerging, nice-to-have trend to experiment with to a legitimate, must-do priority for enterprises.

Basically, get on board the AI train or be left behind.

Read more | >

Regenerative medicine company Frequency Therapeutics is developing new drugs that activate our innate abilities to restore function and reverse degenerative diseases. The company is working on small molecules that selectively activate progenitor cells already present within our bodies to create healthy, functional tissues. Frequency’s initial focus is on hearing loss and multiple sclerosis, and the company has just completed enrolment of a Phase 2b trial in adults with acquired sensorineural hearing loss (SNHL).

Longevity. Technology: Frequency is focused on progenitor cells, which are like stem cells but can only make cells that belong to the same tissue or organ. While progenitor cells remain active in some of our organs and tissues, they can become dormant in others. Frequency’s small molecules are designed to selectively target and induce dormant progenitor cells to create specific cell types to restore tissue structure and function. We caught up with Frequency’s Chief Scientific Officer Dr Chris Loose to learn more.

Nasdaq-listed Frequency was founded in 2014, licensing technology developed by professors Robert Langer from MIT and Jeffrey Karp from Harvard Medical School.

Read more | >

Dr talks taking hardcore science to market without biotech approval risk and the catalyst that is translational research.

We were lucky enough to attend the Longevity Investors Conference last month; this key event attracts those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. To put it succinctly, as MIT Tech Review did recently, LIC “brings academic scientists and biotech companies together with deep-pocketed investors. We’re talking millionaires and billionaires.”

One of the driving forces behind the Longevity Investors Conference is Dr Tobias Reichmuth; a company-builder since the age of 21, Reichmuth has invested in more than 20 startups and is one of the founding partners of Maximon, the longevity company building. Along with his Maximon colleague Marc P Bernegger, Riechmuth launched the Longevity Investors Conference, and we couldn’t pass up the chance to grab some time with him to discuss the current longevity market.

Visit Longevity. Technology — https://bit.ly/3PwtH8Y

Continue reading “Tobias Reichmuth — the longevity market starts now” | >